Haematologica, 2012 Background Mantle cell lymphoma is a clinically heterogeneous disease characterized by overexpression of cyclin D1 protein. Blastoid morphology, high proliferation, and secondary genetic aberrations are markers of aggressive behavior.
Julia Slotta-Huspenina +9 more
doaj +1 more source
Impact of novel therapies for mantle cell lymphoma in the real world setting : a report from the UK's Haematological Malignancy Research Network (HMRN) [PDF]
, 2018 The treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether
Abrahamsson +41 more
core +1 more source
Cutaneous lesions as presentation form of mantle cell lymphoma
Dermatology Reports, 2011 Mantle cell lymphoma is a type of no-Hodgkin lymphoma that affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Here we report a case of mantle cell lymphoma IV Ann Arbor stage with cutaneous lesions on nasal dorsum and ...
Nayra Merino de Paz +6 more
doaj +1 more source
Nanomedicine for the Treatment of Non-Hodgkin Lymphoma [PDF]
, 2019 Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually.
Gandhi, B.Pharm, Tanvi
core +1 more source
Targeted therapy in lymphoma [PDF]
, 2010 Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal ...
Patrick B Johnston +3 more
core +1 more source
Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
Hematology Reports, 2011 The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud +1 more
doaj +1 more source
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas [PDF]
, 2007 Integrative genomic and gene-expression analyses have identified amplified oncogenes in B-cell non-Hodgkin lymphoma (B-NHL), but the capability of such technologies to localize tumor suppressor genes within homozygous deletions remains unexplored.
Agirre-Ena, X. (Xabier) +20 more
core
Telomere protein complexes and their role in lymphoid malignancies [PDF]
, 2017 Telomeres are highly regulated and dynamic complexes that protect the genomic DNA and prevent the end of linear chromosomes from being misrecognized as a broken DNA.
Dos Santos, Patricia Carolina +2 more
core
Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase
Brazilian Journal of Medical and Biological Research, 2006 We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos +4 more
doaj
Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). [PDF]
, 2019 Angioimmunoblastic T-cell lymphoma (AITL) is one of four major subtypes of nodal peripheral T cell lymphoma, characterized by its cell of origin, the follicular helper T-cell (TFH).
Alpdogan, Onder +7 more
core +1 more source